DOP2021000128A - Derivados de oxopiridina sustituidos - Google Patents

Derivados de oxopiridina sustituidos

Info

Publication number
DOP2021000128A
DOP2021000128A DO2021000128A DO2021000128A DOP2021000128A DO P2021000128 A DOP2021000128 A DO P2021000128A DO 2021000128 A DO2021000128 A DO 2021000128A DO 2021000128 A DO2021000128 A DO 2021000128A DO P2021000128 A DOP2021000128 A DO P2021000128A
Authority
DO
Dominican Republic
Prior art keywords
substitute
oxopyridine derivatives
derivatives
thromboembolic
oxopyridine
Prior art date
Application number
DO2021000128A
Other languages
English (en)
Inventor
Lang Dieter
Matthias Gericke Kersten
Anlauf Sonja
Schäfer Martina
Tersteegen Adrian
Heitmeier Stefan
Hillisch Alexander
Röhrig Susanne
Ellerbrock Pascal
Neubauer Thomas
Essig Sebastian
Stampfauss Jan
Wang Hongping
Meng Xianghai
Meier Katharina
Zou Zengqiang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of DOP2021000128A publication Critical patent/DOP2021000128A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a derivados de oxopiridina sustituidos y a procesos para su preparación, y también a su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular trastornos vasculares, preferentemente trastornos trombóticos o tromboembólicos y/o complicaciones trombóticas o tromboembólicas.
DO2021000128A 2018-12-21 2021-06-18 Derivados de oxopiridina sustituidos DOP2021000128A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21
PCT/EP2019/085983 WO2020127504A1 (en) 2018-12-21 2019-12-18 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
DOP2021000128A true DOP2021000128A (es) 2021-09-30

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000128A DOP2021000128A (es) 2018-12-21 2021-06-18 Derivados de oxopiridina sustituidos

Country Status (22)

Country Link
EP (1) EP3898633A1 (es)
JP (1) JP2022514303A (es)
KR (1) KR20210106504A (es)
CN (1) CN113474348A (es)
AR (1) AR117435A1 (es)
AU (1) AU2019407909B2 (es)
BR (1) BR112021009435A2 (es)
CA (1) CA3124220A1 (es)
CL (1) CL2021001613A1 (es)
CO (1) CO2021007908A2 (es)
CR (1) CR20210342A (es)
DO (1) DOP2021000128A (es)
EA (1) EA202191764A1 (es)
EC (1) ECSP21043895A (es)
IL (1) IL283990A (es)
JO (1) JOP20210161A1 (es)
MA (1) MA54521A (es)
MX (1) MX2021007508A (es)
PE (1) PE20211790A1 (es)
SG (1) SG11202104384PA (es)
TW (1) TW202039510A (es)
WO (1) WO2020127504A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220565T1 (hr) * 2018-03-15 2022-06-10 Bayer Aktiengesellschaft Postupak pripreme dva derivata 4-{[(2s)-2-{4-[5-klor-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorbenzamida
CN114105881B (zh) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途
WO2022189278A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
KR20230155505A (ko) 2021-03-09 2023-11-10 바이엘 악티엔게젤샤프트 (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로-메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-5 디벤제나헵타판-74-카르복스아미드의 결정질 형태
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN114560754A (zh) * 2022-02-25 2022-05-31 滁州学院 一种烷基醇的制备方法
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
EP2978425B1 (en) 2013-03-27 2017-09-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
EP3024822B1 (de) 2013-07-23 2017-05-03 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung als faktor xia und plasmakallikrein inhibitoren
US9765070B2 (en) 2013-10-30 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CN106687458B (zh) 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
EP3197872B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
WO2016046156A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
US10138236B2 (en) * 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
WO2016046158A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
JP2018509426A (ja) * 2015-03-19 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト 血栓症の治療のための因子ＸＩａ阻害剤としてのオキソピリジン誘導体
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate

Also Published As

Publication number Publication date
AU2019407909A1 (en) 2021-05-27
SG11202104384PA (en) 2021-05-28
MX2021007508A (es) 2021-08-05
IL283990A (en) 2021-07-29
EA202191764A1 (ru) 2021-10-22
BR112021009435A2 (pt) 2021-08-17
MA54521A (fr) 2022-03-30
KR20210106504A (ko) 2021-08-30
AU2019407909B2 (en) 2023-05-25
EP3898633A1 (en) 2021-10-27
JOP20210161A1 (ar) 2023-01-30
JP2022514303A (ja) 2022-02-10
CN113474348A (zh) 2021-10-01
PE20211790A1 (es) 2021-09-09
CO2021007908A2 (es) 2021-07-19
WO2020127504A1 (en) 2020-06-25
AR117435A1 (es) 2021-08-04
CR20210342A (es) 2021-08-09
CA3124220A1 (en) 2020-06-25
CL2021001613A1 (es) 2021-12-03
TW202039510A (zh) 2020-11-01
ECSP21043895A (es) 2021-07-30

Similar Documents

Publication Publication Date Title
DOP2021000128A (es) Derivados de oxopiridina sustituidos
ECSP18001308A (es) Derivados de oxopiridina sustituidos
ECSP20072258A (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
CO2019002361A2 (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
CL2021000930A1 (es) Piridazinas novedosas
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CO2019011285A2 (es) N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso
DOP2024000024A (es) Derivados de s-alaninato sustituidos
NI201500168A (es) Benzoxazoles sustituidos
WO2016092377A3 (ru) Композиция, содержащая глюкозамин, фруктобарат кальция и витамин d для лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов и позвоночника